Clinical trials: Myocardial Ischaemia
Stable Angina
A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes
Purpose: This study is to determine the effect of T89(Dantonic®)on P450 enzymes. This study will help determine which types of drugs may interact with T89.
- Trial name
- NCT01473888
- Testing
- T89(Dantonic)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tasly Pharmaceuticals, Inc.
Coronary Artery Disease
Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent: A Optical Coherent Tomography Study
Our hypothesis is to test that 1) The safety and efficacy of Nano+ DES in patients with de novo lesions; 2) A low neointimal hyperplasia after Nano+ DES implantation due to its effective and sufficient antiproliferative drug; 3)…
- Trial name
- NCT01925027
- Testing
- Nano+ DES
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 45 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.
Healthy Volunteers
Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884
A Phase 1, single dose study with 4 cohorts of ascending doses and an optional Japanese cohort designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of MEDI5884 in healthy volunteers
- Trial name
- NCT03001297
- Testing
- MEDI5884 Dose 1, MEDI5884 Dose 2, MEDI5884 Dose 3
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Left Ventricular Dysfunction, Coronary Artery Disease
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health…
- Trial name
- PROTECT IV (NCT04763200)
- Testing
- Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
- Where
- 110 sites in United States, Canada and 5 more
- Volunteers
- 1,252 people
- Sponsor
- Abiomed Inc.
Coronary Artery Stenosis
De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions
The study will enroll patients with angiographically significant coronary de novo lesions. Subjects will be randomized 1:1 and treated with a Lutonix catheter either before or after bare-metal stenting (BMS).
- Trial name
- NCT00934752
- Testing
- Lutonix Paclitaxel-Coated Balloon
- Where
- 3 sites in Netherlands
- Volunteers
- 24 people
- Sponsor
- C. R. Bard
Coronary Artery Disease
Data Aquisition for Optimization of Coronary Artery Disease Algorithm
The purpose of the study is to optimize an already existing algorithm for diagnosing atherosclerosis of the coronary arteries (CAD, Coronary Artery Disease).
- Trial name
- NCT01090947
- Testing
- ProtoCAD
- Where
- Denmark
- Volunteers
- 729 people
- Sponsor
- Acarix
Coronary Artery Disease, Heart Diseases
Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
Coronary angiography-derived FFR assessment (AngioQFA) is a novel technique for physiological lesion assessment based on 3-dimensional (3D) quantitative coronary angiography (QCA) and virtual hyperemic flow derived from contrast…
- Conditions
- Coronary Artery Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- NCT06039748
- Testing
- AngioQFA
- Where
- 5 sites in China
- Volunteers
- 330 people
- Sponsor
- Shenzhen Raysight Intelligent Medical Technology Co., Ltd.
Angina Pectoris
Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization
The purpose of this study is to determine whether a one-time intracoronary infusion of Ad5FGF-4 is effective in reducing the time to onset myocardial ischemia as measured by exercise treadmill testing and improving myocardial…
- Trial name
- AWARE (NCT00438867)
- Testing
- Ad5FGF-4
- Where
- 47 sites in United States
- Volunteers
- 300 people
- Sponsor
- Cardium Therapeutics
Myocardial Ischemia, Hypertension
ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation
Primary Objective The main objective of this study is to assess if a two-month regimen of irbesartan in patients hospitalized for acute coronary syndrome without ST segment elevation can reduce inflammation markers (ie hsCRP), in…
- Trial name
- NCT00296218
- Testing
- Irbesartan
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 440 people
- Sponsor
- Sanofi
Ischemic Heart Disease, Coronary Arteriosclerosis
A Randomized Clinical Trial of Adipose-derived Stem Cells in Treatment of Non Revascularizable Ischemic Myocardium
The purpose of this study is to establish safety and feasibility of utilizing Adipose Derived Stem \& Regenerative Cells (ADRCs) in patients who have areas of myocardium that are not revascularizable and have demonstrated…
- Conditions
- Ischemic Heart Disease, Coronary Arteriosclerosis, Cardiovascular Disease, Coronary Disease
- Trial name
- NCT00426868
- Testing
- Direct injection of ADRCs into the Left Ventricle
- Where
- 4 sites in Denmark, Netherlands and 1 more
- Volunteers
- 27 people
- Sponsor
- Cytori Therapeutics
Coronary Arteriosclerosis
Support C Post-Market Registry
To collect post marketing surveillance data on consecutive patients with coronary heart disease intended to be or treated by the drug eluting Support C PTCA balloon catheter when used according to the Instructions for Use.
- Trial name
- NCT06678490
- Where
- 12 sites in Czechia, Germany and 2 more
- Volunteers
- 282 people
- Sponsor
- OrbusNeich
Coronary Occlusion
Safety and Efficacy of the CiTop™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries
The CiTop™ guidewire Coronary study is a feasibility open label study, to evaluate the safety and efficacy of the CiTop™ Guidewire for crossing chronic total occlusion in Coronary arteries.
- Trial name
- NCT00618020
- Testing
- CiTop(tm) Guidewire
- Where
- India
- Volunteers
- 10 people
- Sponsor
- Ovalum
CAD - Coronary Artery Disease
Angiogram Based Fractional Flow Reserve FFRangio - A Validation Study
In the present study we aim at validating the computation of FFRangio values from the angiogram by comparing them to measured wire-based FFR values, in a larger scale and in a completely blinded manner.
- Trial name
- NCT03005028
- Where
- Israel
- Volunteers
- 184 people
- Sponsor
- CathWorks Ltd.
Atherosclerosis, Myocardial Ischemia
Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)
The study is designed to assess safety and effects of vorapaxar, when added to standard of care (aspirin and clopidigrel), in Japanese subjects with acute coronary syndrome.
- Conditions
- Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT00684203
- Testing
- Vorapaxar, Aspirin, Clopidogrel
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Myocardial Infarction
Determining the Optimal Cut-off Point of PEA by Corsens Device for Discriminating Between MI and Non-MI Subjects
Acute Myocardial Infarction (MI) is still the leading cause of death in the western world. Early warning (chest pain) signs of an acute MI are often misinterpreted and disregarded.
- Trial name
- NCT02723851
- Testing
- Corsens
- Volunteers
- 76 people
- Sponsor
- Corsens Medical LTD
Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events
To estimate ischemic event rates in individuals with established atherosclerotic cardiovascular disease (ASCVD) and no prior acute ischemic events, comparing alirocumab with no Proprotein Convertase Subtilisin/Kexin type 9…
- Trial name
- OPTIMUS-EPIC (NCT07734753)
- Testing
- Alirocumab, Comparator: No PCSK9i Therapy (monoclonal antibodies or small interfering RNA agents)
- Where
- Netherlands
- Volunteers
- 4,006 people
- Sponsor
- Sanofi
Stable Angina Pectoris
Efficacy and Safety Study of Total Flavonoids of Propolis Dropping Pill to Treat Angina Pectoris
The purpose of this study is to confirm the efficacy and safety of total flavonoids of propolis dropping pill to treat angina pectoris, evaluated by total exercise time of treadmill exercise test.
- Trial name
- NCT01453582
- Testing
- Total Flavonoids of Propolis dropping pill
- Where
- 13 sites in China
- Volunteers
- 478 people
- Sponsor
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
Stable Coronary Artery Disease
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in Hispanic patients with stable coronary artery disease.
- Trial name
- NCT01523366
- Testing
- Ticagrelor, Clopidogrel
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- AstraZeneca
Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease
EXCEL Clinical Trial
To establish the safety and efficacy of the commercially approved XIENCE Family Stent System (inclusive of XIENCE PRIME, XIENCE V, XIENCE Xpedition and XIENCE PRO [for use outside the United States [OUS] only]) in subjects with…
- Conditions
- Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease
- Trial name
- EXCEL (NCT01205776)
- Testing
- Percutaneous Coronary Intervention, CABG
- Where
- United States
- Volunteers
- 1,905 people
- Sponsor
- Abbott Medical Devices
Coronary Heart Disease
Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus
The purpose of this observational protocol is to evaluate the use of everolimus in routine clinical practice for heart transplants. Primary outcome measures: incidence of acute rejection episodes Secondary outcomes: safety
- Trial name
- NCT00134940
- Where
- 6 sites in Austria, Germany
- Volunteers
- 100 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.